SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-029868
Filing Date
2024-08-01
Accepted
2024-08-01 08:00:24
Documents
18
Period of Report
2024-08-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 52787
2 ex4-1.htm EX-4.1 127594
3 ex4-2.htm EX-4.2 121723
4 ex10-1.htm EX-10.1 76796
5 ex10-2.htm EX-10.2 44129
6 ex10-2_001.jpg GRAPHIC 22514
  Complete submission text file 0001493152-24-029868.txt   713444

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE zvsa-20240801.xsd EX-101.SCH 3012
8 XBRL LABEL FILE zvsa-20240801_lab.xml EX-101.LAB 34240
9 XBRL PRESENTATION FILE zvsa-20240801_pre.xml EX-101.PRE 22357
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3815
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

IRS No.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41184 | Film No.: 241164421
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)